Prevalence of Neuropsychiatric Adverse Effects in HIV Patients Treated with Dolutegravir
DOI:
https://doi.org/10.24950/rspmi/original/64/1/2019Keywords:
Anti-HIV Agents/adverse effects, Dolutegravir/adverse effects, HIV Infections/drug therapy, Mental Disorders/ chemically inducedAbstract
Introduction: Dolutegravir may be presented as a high efficiency level therapeutic option for naive or experimented patients, namely for simplifying therapies and achievement of a
good interactions profile. Results of approval studies sustain
it as safe and well tolerated. However, more recent studies
have raised doubts on its safety profile, for instance at the
neuropsychiatric effects developing level.
Our aim was to determine prevalence of neuropsychiatric effects or no neuropsychiatric effects on a HIV infected patient
population with dolutegravir on their antiretroviral therapy.
Material and Methods: Transversal observational study of the
cohort of patients followed at Oporto’s Hospital Immunodeficiency Department, subjected to dolutegravir therapy. After the introduction of dolutegravir, clinical files have been
browsed and questionnaires have been placed for evaluation of adverse effects.
Results: Seventy patients have been identified as under dolutegravir therapy, of which 7 have been excluded for lack
of data. Five patients were naive as to antiretroviral therapy.
Prevalence rate for neuropsychiatric effects and other effects
15 PUBLICAÇÃO TRIMESTRAL
VOL.26 | N.º 1 | JAN/MAR 2019
ARTIGOS ORIGINAIS
was 20.6% and 25.4%, respectively. The main neuropsychiatric effects were insomnia, nervousness/anxiety and depressive humor, more frequently observed on female patients
[(34.6% vs 10.8% of the men); OR 4.37; CI 95% 1.17-16.27;
p = 0.028]. Despite the results, therapy has not been discontinued.
Conclusion: Observation of a high rate of neuropsychiatric effects (20.6%), similar to a recently published study. However,
these neuropsychiatric effects did not lead to the discontinuation of dolutegravir therapy on any patient. In spite of the limited resources at their disposal for this study, the authors
strongly stress the need for further studies and evaluations of
the real impact of neuropsychiatric effects somehow associated to dolutegravir
Downloads
References
Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor- naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013; 382: 700–8. doi: 10.1016/S0140-6736(13)61221-0.
Clotet B, Feinberg J, van Lunzen J, Khuong-Josses MA, Antinori A, Dumitru I, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviralnaive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet. 2014; 383: 2222–31. doi: 10.1016/S0140-6736(14)60084-2.
Raffi F, Jaeger H, Quiros-Roldan E, Albrecht H, Belonosova E, Gatell JM, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naïve adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2013; 13: 927–35. doi: 10.1016/S1473-3099(13)70257-3.
Stellbrink HJ, Reynes J, Lazzarin A, Voronin E, Pulido F, Felizarta F, et al. Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study. AIDS. 2013; 27: 1771– 8. doi: 10.1097/QAD.0b013e3283612419.
Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutiérrez F, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013; 369: 1807–18. doi: 10.1056/NEJMoa1215541.
Hightower KE, Wang R, Deanda F, Johns BA, Weaver K, Shen Y, et al. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob Agents Chemother. 2011; 55: 4552–9. doi: 10.1128/AAC.00157-11.
Todd S, Raffert P, Walker E, Hunter M, Dinsmore WW, Donnelly CM, et al. Early clinical experience of dolutegravir in a HIV cohort in a larger teaching hospital. Int J STD AIDS. 2017; 28:1074-81. doi: 10.1177/0956462416688127
De Boer MG, van den Berk GE, van Holten N, Oryszcyn JE, Dorama W, Moha DA, Brinkman K. Intolerance of dolutegravir- containing combination antiretroviral therapy regimens in real- life clinical practice. AIDS. 2016; 30:2831–4. doi: 10.1097/QAD.0000000000001279.
Menard A, Montagnac C, Solas c, Meddeb L, Dhiver C, Tomei C, et al. Neuropsychiatric adverse effects on dolutegravir: an emerging concern in Europe. AIDS. 2017; 15:31:1201-3. doi: 10.1097/QAD.0000000000001459.
Hoffmann C, Welz T, Sabranski M, Kolb M, Wolf E, Stellbrink H, et al. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med. 2017; 18:56-63. doi: 10.1111/ hiv.12468.
Dubé B, Benton T, Cruess DG, Evans DL. Neuropsychiatric manifestations of HIV infection and AIDS. J Psychiatry Neurosci. 2005;30:237–46.
Rabkin JG. HIV and depression: 2008 review and update. Curr HIV/AIDS Rep. 2008;5:163–71.
Lowther K, Selman L, Harding R, Higginson IJ. Experience of persistent psychological symptoms and perceived stigma among people with HIV on antiretroviral therapy (ART): a systematic review. Int J Nurs Stud. 2014;51:1171– 89. doi: 10.1016/j.ijnurstu.2014.01.015.
Chen X, Redline S, Shields AE, Williams DR, Williams MA. Associations of allostatic load with sleep apnea, insomnia, short sleep duration, and other sleep disturbances: findings from the National Health and Nutrition Examination Survey 2005 to 2008. Ann Epidemiol. 2014;24:612–9. doi: 10.1016/j. annepidem.2014.05.014.
Zhang J, Lamers F, Hickie IB, He JP, Feig E, Merikangas KR. Differentiating nonrestorative sleep from nocturnal insomnia symptoms: demographic, clinical, inflammatory, and functional correlates. Sleep. 2013;36:671–9. doi: 10.5665/sleep.2624.
Gunnell D, Harbord R, Singleton N, Jenkins R, Lewis G. Factors influencing the development and amelioration of suicidal thoughts in the general population. Br J Psychiatry. 2004;185:385–93.
King M, Semlyen J, Tai SS, Killaspy H, Osborn D, Popelyuk D, et al. A systematic review of mental disorder, suicide, and deliberate self harm in lesbian, gay and bisexual people. BMC Psychiatry. 2008;8:70. doi: 10.1186/1471- 244X-8-70.
Yoshimasu K, Kiyohara C, Miyashita K; Stress Research Group of the Japanese Society for Hygiene. Suicidal risk factors and completed suicide: meta- -analyses based on psychological autopsy studies. Environ Health Prev Med. 2008;13:243–56.
Givens N, Puccini S, Vannappagari V, Givens N, Puccini S, Vannappagari V, et al. Psychiatric symptoms in patients receiving dolutegravir. J Acquir Immune Defic Syndr. 2017;74:423-31. doi: 10.1097/QAI.0000000000001269.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2023 Medicina Interna
Open Access
